Status: Recruiting
Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer
This example Phase 1 study is designed to evaluate the safety, tolerability, feasibility, and preliminary anti-tumor activity of ETB-DualNK-01, an allogeneic dual-target PSMA/PSCA CAR-NK cell therapy, in adults with metastatic castration-resistant prostate cancer (mCRPC). Part A uses dose escalation to determine the maximum tolerated dose and/or recommended Phase 2 dose. Part B expands at the selected dose in biomarkerconfirmed disease.
Participants needed: 36
Trial details
Phase: Phase 1Age: 18+Biological sex: MaleType: InterventionalSponsor: Beijing BiotechUpdated: Jun 11, 2026Locations: 1
Eligibility criteria
Male participant age 18 years or older. [+9]
Active central nervous system metastases or leptomeningeal disease. [+8]